These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36346099)

  • 41. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
    Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
    Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of primary tumor sidedness in patients with non-metastatic IBD related CRC - Is it the exception to the rule?
    Kamphues C; Lefevre JH; Wang J; Amini N; Beaugerie L; Kuehn F; Park SH; Andreatos N; Lauscher JC; Enea D; Lehmann KS; Peru N; Weixler B; Kirchgesner J; Degro CE; Pozios I; van Beekum CJ; Schölch S; Zambonin D; Schineis C; Loch FN; Geka D; Theoxari M; Wu B; Wang PP; Antoniou E; Pikoulis E; Moussata D; Theodoropoulos G; Ouaissi M; Seeliger H; Inaba Y; Scaringi S; Reißfelder C; Vilz TO; Lin C; Yang SK; Beyer K; Renz BW; Sasaki K; Margonis GA; Svrcek M; Kreis ME
    Surg Oncol; 2022 Dec; 45():101874. PubMed ID: 36257179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring the prognostic impact of tumor sidedness in ovarian cancer: A population-based survival analysis of over 10,000 patients.
    Bairi KE; Trapani D; Page CL; Saad A; Jarroudi OA; Afqir S
    Cancer Treat Res Commun; 2022; 33():100625. PubMed ID: 36057142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
    Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
    Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
    Kratz JD; Uboha NV; Lubner SJ; Mulkerin DL; Clipson L; Yi Y; Yu M; Matkowskyj KA; LoConte NK; Deming DA
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1442-1450. PubMed ID: 30545991
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes.
    Saravani K; Salarzaei M; Parooie F
    Hum Antibodies; 2021; 29(4):275-284. PubMed ID: 34334388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival outcome and prognostic factors for early-onset and late-onset metastatic colorectal cancer: a population based study from SEER database.
    Ren B; Yang Y; Lv Y; Liu K
    Sci Rep; 2024 Feb; 14(1):4377. PubMed ID: 38388566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.
    Sunakawa Y; Mogushi K; Lenz HJ; Zhang W; Tsuji A; Takahashi T; Denda T; Shimada K; Kochi M; Nakamura M; Kotaka M; Segawa Y; Tanioka H; Negoro Y; Moran M; Astrow SH; Hsiang J; Stephens C; Fujii M; Ichikawa W
    Mol Cancer Ther; 2018 Dec; 17(12):2788-2795. PubMed ID: 30275242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathological Characteristics and Prognostic Factors in Ovarian Metastases from Right- and Left-Sided Colorectal Cancer.
    Kubeček O; Laco J; Špaček J; Kubečková A; Petera J; Krulichová IS; Bezrouk A; Filip S; Kopecký J
    Curr Oncol; 2021 Aug; 28(4):2914-2927. PubMed ID: 34436021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
    Fischer LE; Stintzing S; von Weikersthal LF; Modest DP; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Giessen-Jung C; Uhlig J; Peuser B; Denzlinger C; Stahler A; Weiss L; Heinrich K; Held S; Jung A; Kirchner T; Heinemann V
    Br J Cancer; 2022 Sep; 127(5):836-843. PubMed ID: 35637412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
    Noepel-Duennebacke S; Arnold D; Hertel J; Tannapfel A; Hinke A; Hegewisch-Becker S; Reinacher-Schick A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e733-e739. PubMed ID: 30145148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival outcome and prognostic factors for colorectal cancer with synchronous bone metastasis: a population-based study.
    Li X; Hu W; Sun H; Gou H
    Clin Exp Metastasis; 2021 Feb; 38(1):89-95. PubMed ID: 33420873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study.
    Chibaudel B; André T; Tournigand C; Louvet C; Benetkiewicz M; Larsen AK; de Gramont A
    Clin Colorectal Cancer; 2020 Sep; 19(3):200-208.e1. PubMed ID: 32303437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
    Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; Ronzoni M; Racca P; Loupakis F; Zaniboni A; Tonini G; Buonadonna A; Marmorino F; Allegrini G; Granetto C; Masi G; Zagonel V; Sensi E; Fontanini G; Boni L; Falcone A
    Ann Oncol; 2018 Jul; 29(7):1528-1534. PubMed ID: 29873679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey.
    Cakan B; Acikgoz O; Bilici A; Demir T; Basak Oven B; Hamdard J; Olmuscelik O; Olmez OF; Seker M; Yildiz O
    J BUON; 2021; 26(5):1908-1917. PubMed ID: 34761599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
    Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.